Fig. 1.

PFS and OS among all patients according to baseline NLR (a, b) and NLR variations between the first and the fourth administration (c, d). a Is referring to the PFS of patients of the whole cohort according to the baseline NLR value (below or above the median NLR baseline value in the whole cohort). b Is referring to the OS of patients of the whole cohort according to the baseline NLR value (below or above the median NLR baseline value in the whole cohort). c Is referring to the PFS of patients of the whole cohort according to the NLR variation between the first and the fourth nivolumab administration. d Is referring to the OS of patients of the whole cohort according to the NLR variation between the first and the fourth nivolumab administration